Human microbiome drugs market to be valued at $2.13b by 2031

By end user, the hospitals and clinics segment held the largest market share in 2024.

According to MarketsandMarkets, the human microbiome drugs market is expected to reach $2.13b by 2031, growing at a CAGR of 35.2%.

The industry’s expansion is attributed to collaborations between CDMOs, biotech companies and academic institutions to advance bioprocess innovation and scale microbiome research into GMP-compliant production.

Additionally, developments in microbial engineering, high-throughput analysis, and automation have improved culture control and product consistency, enabling the next generation of live biotherapeutics and probiotics.

“Innovations in encapsulation, lyophilization and delivery technologies are also increasing the variety and effectiveness of microbiome-based products that can be manufactured,” the report states.

The hospitals and clinics segment will account for the largest market share in terms of end user in 2024, driven by well-trained personnel, infrastructure, and strong capabilities for patient participation in follow-up monitoring.

It added: “The rising prevalence of chronic diseases and growing demand for microbiome-targeted therapies further strengthens hospitals and clinics as the most important end-user sector.”